Dosing & Administration
Retatrutide is given as a once-weekly subcutaneous injection, and the single most important practical fact about it is…
How retatrutide is given in trials, and why dose escalation is everything
Retatrutide is given as a once-weekly subcutaneous injection, and the single most important practical fact about it is dose escalation: trials start low and step up slowly so the gut can adapt and nausea stays manageable. This unit explains the principles behind that schedule.
A blunt caveat first: this is education only. Retatrutide is investigational, there is no approved dosing label, and it cannot legally be used in compounding. Nothing here is a protocol to follow. The goal is to understand how the drug is administered in research, not to guide any personal use.
Key terms
The route and the weekly rhythm
In trials, retatrutide is injected under the skin once a week, the same rhythm as semaglutide and tirzepatide. The weekly schedule is possible only because of the albumin-binding chemistry from the molecule unit, which stretches the drug action across seven days. The phases below show the broad arc of a trial regimen.
The rhythm is simple in outline: one injection a week, ramped up gradually. The specifics, exact doses and intervals, are study-defined and outside the scope of an education course. What matters conceptually is that the schedule is built around gentle, stepwise increases.
AdvancedWhy weekly, not daily
Weekly dosing is a tolerability and adherence win: fewer injections and steadier drug levels than a short-acting daily drug. It works only because the albumin-bound reservoir releases the drug slowly, keeping levels in range across the whole week.